NCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
41 trialsNCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06984146 2025-11-26
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Recruiting
NCT07002216 2025-11-03
BrECADD
University of Miami
Phase 2 Recruiting
NCT05922904 2025-10-10
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03712202 2024-11-06
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02191930 2024-08-23
BVB
University of Cologne
Phase 2 Completed
NCT01858922 2024-01-12
TXCH-HD-12A
Baylor College of Medicine
Phase 2 Completed
NCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
NCT02181738 2023-11-28
CheckMate 205
Bristol-Myers Squibb
Phase 2 Completed
NCT02398240 2023-10-26
Brentuximab for Newly Diagnosed Hodgkin Disease
New York Medical College
Phase 2 Completed
NCT00352027 2023-09-22
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01030900 2022-10-06
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02292979 2022-08-19
BREACH
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT00000626 2021-10-27
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT02298283 2021-07-26
BRAPP2
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT01132807 2021-06-14
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02505269 2020-08-24
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT00002715 2020-08-12
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
Stanford University
Phase 2 Completed
NCT00398554 2020-03-26
Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Completed
NCT01476410 2020-02-17
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT03527628 2019-11-18
(Optimist)
King Abdullah International Medical Research Center
Phase 2 Unknown
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT01569204 2018-10-29
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
University of Cologne
Phase 2 Completed
NCT00369681 2018-08-27
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00026208 2018-07-24
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Stanford University
Phase 2 Completed
NCT01534078 2018-02-20
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT00086801 2016-07-01
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00592111 2015-12-23
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00512980 2015-12-03
PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
University of Cologne
Phase 2 Terminated
NCT00666484 2014-12-04
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
University College, London
Phase 2 Completed
NCT00225173 2014-08-27
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Stanford University
Phase 2 Terminated
NCT00004010 2014-02-26
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
Children's Oncology Group
Phase 2 Completed
NCT00003262 2013-09-20
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00504504 2013-07-09
Rituximab and ABVD for Hodgkin's Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002714 2013-05-15
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease
National Cancer Institute (NCI)
Phase 2 Completed
NCT01404936 2013-02-01
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00797472 2011-07-20
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
American Scitech International
Phase 2 Unknown